sarilumab (Kevzara)

Sarilumab is accepted for restricted use within NHS Scotland in combination with methotrexate for treatment of moderately to severely active rheumatoid arthritis in adults who have responded inadequately to, or who are intolerant to ≥1 DMARDs.

Sarilumab can also be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate. In patients with severe disease inadequately controlled by a TNF antagonist, it may be used in patients ineligible to receive rituximab.

 

The advice is contingent upon the continuing availability of the Patient Access Scheme PAS in NHS Scotland or a list price that is equivalent or lower.